In 2021, health officials started testing airline passengers who passed through a New York airport to identify imported emerging infectious diseases, part of the U.S. national biosecurity initiative.
Over the past three years, more than 300,000 travelers from over 135 countries have participated each year in the U.S. Centers for Disease Control and Prevention (CDC) Traveler-based Genomic Surveillance (TGS) program.
The TGS has been offering testing services in Los Angeles, Newark, Seattle, Boston, San Francisco, NYC (JFK), and Washington, DC (IAD).
Read More
